In Germany, Screening for COVID-19 with the ARIES® System

Clinical lab scientist describes his experience establishing a two-step diagnostic algorithm for COVID-19 Scientists in clinical labs worldwide have worked night and day in the COVID-19 pandemic to develop, validate, and implement new diagnostic tests for patients believed to be infected by the SARS-CoV-2 virus. While each lab’s experiences are slightly different, there are certain […]

Read More…

Riverview Health Shares How They Are Managing Antibiotic Resistance Through Improved Testing and Teamwork

Riverview Health is a full-service, CLIA certified, and CAP accredited laboratory. They provide clinical testing services for hospitalized patients 24 hours a day, seven days a week, and serve as a reference laboratory for doctors’ offices and extended care facilities throughout central Indiana. Diagnostic labs require accurate testing and rapid turnaround time Riverview is unique […]

Read More…

Five New Verigene Studies to be Presented at ICAAC 2015

New clinical data for two Verigene infectious disease tests will be presented during Sepsis Awareness Month at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego this week. The five Verigene studies highlight the performance of the Verigene® Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Test (BC-GN), as well as the […]

Read More…

Peer-to-Peer: Why Flexible Testing?

At last month’s Association for Molecular Pathology (AMP) Annual Meeting in Austin, TX, Margie Morgan, PhD, Scientific Director of Microbiology at Cedars-Sinai Medical Center in Los Angeles, CA, discussed the advantages of flexible multiplex tests over the currently available fixed-panel, fixed-price respiratory, and gastrointestinal tests. In her talk, Dr. Morgan described how flexible tests will […]

Read More…

The “Phantom Menace” Superbug Reveals Dark Side of Antibiotic Misuse

Cases of a threatening superbug, nicknamed the “phantom menace,” are rising in the U.S., according to the Centers for Disease Control and Prevention (CDC). The phantom menace superbug produces OXA-48-like carbapenemases and has been observed most frequently in Enterobacteriaceae isolates. This type of carbapenem-resistant Enterobacteriaceae (CRE), however, has a lower level of resistance than other strains of CRE. As a result, these isolates have not been tested for and identified as frequently as other CREs and have widely escaped detection by health officials, earning it the nickname “phantom menace.” […]

Read More…

Four New Verigene Outcomes Studies to be Presented at IDWeek 2015

Four new outcomes studies associated with implementation of Verigene® Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Tests will be presented during IDWeek 2015 in San Diego this week. These studies focus on the clinical impact that BC-GP and BC-GN paired with pharmacy and/or antimicrobial stewardship team (AST) intervention can have on optimization of antimicrobial therapy […]

Read More…

New BC-GN Outcomes Study Demonstrates Significant Reduction in Mortality

A new study by Tamar Walker et al from Keck School of Medicine of the University of Southern California demonstrated a statistically significant reduction in 30-day mortality and mortality associated with multidrug-resistant organisms following the implementation of the Verigene® Gram-Negative Blood Culture Test (BC-GN). This pre-post study was conducted at Keck Medical Center in Los Angeles, California and was published in the peer reviewed Journal of Clinical Microbiology under the title “Clinical Impact After Laboratory Implementation of the Verigene Gram-Negative Bacteria Microarray for Positive Blood Cultures.”

[…]

Read More…

Nanosphere: There’s Gold In Its Diagnostic Tools

In a profile on Nanosphere, Seeking Alpha’s Cory Renauer concludes: “As a long term investor, I see gold in its Verigene System, both literally and figuratively. Its current number of diagnostics already cleared by major regulators, make it a cost effective addition to almost any hospital based laboratory. Furthermore, its 24/7 availability, and rapid turnaround will save lives, lots of them.” […]

Read More…

CDC Reports 1 in 7 HAIs Caused by Antibiotic-Resistant Superbugs

A new report from the Centers for Disease Control and Prevention (CDC) shows that one in every 25 patients develops an infection during a hospital stay, with one in every seven of these infections being caused by a potentially deadly superbug. This one-in-seven statistic increases to one in four in longer term hospitals. […]

Read More…